Skip to main content

J&J Appeals To Discard $2.5 M Risperdal Verdict

J&J Appeals To Discard $2.5 M Risperdal Verdict

J&J Appeals To Discard $2.5 M Risperdal Verdict

Introduction

Risperdal manufacturer, Johnson & Johnson's unit, requested a Pennsylvania appeals court to discard a $2.5 million verdict against them. J&J asserted that the trial judge prevented the use of a scientific article to challenge an expert's opinion that Risperdal use leads to abnormal breast growth in young boys.

The verdict in question was the second-largest against Risperdal makers awarded to the plaintiff in February 2015. The plaintiff consumed the drug for a period of five years to treat autism-related behavioral issues. His parents claimed his abnormal breast growth was the result of Risperdal consumption.

Over 7,000 Risperdal product liability lawsuits against J&J are filed in the Pennsylvania State Court. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!